COMP <GO>
ADAG vs ANTX // EV/EBITDA & P/E VALUATION
Adagene Inc. (NASDAQ) VS. AN2 Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ADAG 3
— ANTX 1
■ METRIC PARITY
LAST: $2.51 (-6.34%) • MKT CAP: $177.0M
valuation
—
LAST: $4.53 (-3.41%) • MKT CAP: $177.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADAG VS. ANTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADAG | ANTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -8.85% | -16.86% | +8.01 | ADAG | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 3/9 | +2.00 | ADAG | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.5 | 54.0 | -10.49 | ANTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $177.0M | $177.0M | $35.3K | ADAG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADAG REV | ANTX REV | ADAG GROSS % | ANTX GROSS % | ADAG FCF | ANTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $7.7M | $0 | — | — | -$15.7M | -$29.8M |
| FY 2024 | $103.2K | $0 | — | — | -$29.7M | -$49.3M |
| FY 2023 | $18.1M | $0 | — | — | -$28.5M | -$53.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADAG // BETA —
ANTX // BETA —